Understanding the VRd Regimen for Newly Diagnosed Myeloma

Understanding the VRd Regimen for Newly Diagnosed Myeloma discusses a highly effective “triplet” (three-drug) therapy that has proven to be both highly effective and well tolerated. The VRd regimen combines three classes of drugs, with each drug attacking myeloma in a different way while enhancing the activity of the others. The combination of Velcade® (bortezomib) with Revlimid® (lenalidomide) and dexamethasone is currently considered the standard of care for patients with newly diagnosed myeloma.